Interferon (IFN) regulatory factor-1 (IRF-1) is a transcription factor that has apoptotic anti-tumor activity. In breast cancer cell types, IRF-1 is implicated in mediating apoptosis by both novel and established anti-tumor agents, including the anti-estrogens tamoxifen and faslodex. Here we demonstrate that in MDA468 breast cancer cells, apoptosis by IFN-c is mediated by IRF-1 and IFN-c, and IRF-1-induced apoptosis is caspase-mediated. IRF-1 induction results in cleavage of caspase-8, -3 and -7, and application of caspase inhibitors attenuate activated cleavage products. IRF-1-induced apoptosis involves caspase-8 since apoptosis is significantly decreased by the caspase-8-specific inhibitor IETD, c-FLIP expression and in caspase-8-deficient cancer cells. Furthermore, we demonstrate that IRF-1-induced apoptosis requires fas-associated death domain (FADD) since dominant-negative FADD expressing cells resist IRF-1-induced apoptosis and activated downstream products. Immunofluorescent studies demonstrate perinuclear colocalization of FADD and caspase-8. Despite the known role of FADD in mediating death-ligand induced apoptosis, neutralizing antibodies against classical death receptors do not inhibit IRF-1 induced apoptosis, and no secreted ligand appears to be involved since MDA468 coincubated with IRF-1 transfected cells do not apoptose. Therefore, we demonstrate that IRF-1 induces a ligand-independent FADD/caspase-8-mediated apoptosis in breast cancer cells.
Introduction
Interferon (IFN) regulatory factor-1 (IRF-1), a transcription factor induced by IFNs, cytokines, retinoids, DNA damage and even anti-estrogens, upregulates specific genes involved in growth regulation, immune activation and inflammation. The role of IRF-1 as a tumor suppressor is well established; for example, IRF-1À/À embryonic fibroblasts (EFs) are transformed by introduction of just one oncogene (Tanaka et al., 1994a) , while wild type EFs usually require two. Also, NIH3T3 cells transformed by oncogenes c-myc and fosB can revert to a normal phenotype by ectopic expression of IRF-1 (Tanaka et al., 1994b) . We also demonstrated that IRF-1 overexpression in an aggressive mouse sarcoma causes marked tumor suppression in vitro and in vivo (Yim et al., 1997) .
Although IRF-1 has been shown to inhibit growth in response to agents such as IFN-g (Yim et al., 2003) and to mediate apoptosis in studies of IRF-1À/À cells, which are resistant to apoptosis (Tanaka et al., 1994a) , it has been difficult to study the direct effects of IRF-1 expression since this growth inhibitory transcription factor makes it difficult to identify and expand stable transfectants (Kirchhoff et al., 1993) . However, there have been several studies using inducible IRF-1 systems that have demonstrated apoptosis (Kirchhoff and Hauser, 1999; Sanceau et al., 2000) .
Recently, we constructed and characterized a recombinant adenovirus for IRF-1 (Ad-IRF-1), which has greater than 95% transduction efficiency and allowed us to perform real-time analysis of apoptosis. IRF-1 overexpression resulted in caspasemediated apoptosis in two mouse breast cancer cell lines, with caspase-3 activation, caspase-3 cleavage, and PARP cleavage. Interestingly, two non-malignant breast cell lines similarly transduced showed no cell death . Furthermore, Ad-IRF-1 pre-infection of cells and intratumoral injection of established tumors caused significant growth inhibition of breast cancer tumors in vivo. We additionally demonstrated (Pizzoferrato et al., 2004 ) that overexpression of IRF-1 in two human breast cancer cell lines resulted in apoptosis in vitro and in vivo, with decreased expression of the anti-apoptotic protein, survivin.
IRF-1 not only induces apoptosis, but is also a necessary mediator of apoptosis for agents against breast cancer including Mullerian inhibiting substance (MIS) (Gupta et al., 2005) , faslodex (Bouker et al., 2004) , and in E6 expressing HMECs, tamoxifen (Bowie et al., 2004) and reconstituted extracellular matrix (Bowie et al., 2006) . Despite the expanding role of IRF-1 in mediating apoptosis by various agents, the mechanism of IRF-1-induced apoptosis has been largely unstudied. Here we confirm that IFN-g induces caspasemediated apoptosis in the breast cancer cell line MDA468 and that IRF-1 both mediates this apoptosis and elicits caspase-mediated apoptosis when overexpressed. IRF-1 induces caspase-8, -3 and -7 cleavage as well as bid cleavage and release of cytochrome c and Smac/DIABLO from mitochondria. We show that caspase-8 is a proximal caspase cleavage event and that fas-associated death domain (FADD) dominant negative cells abrogate IRF-1-induced apoptosis. FADD also appears to colocalize with caspase-8 in a perinuclear location with IRF-1 overexpression. Despite the involvement of FADD and caspase-8, we show that neutralizing antibodies to death receptors are ineffective in reducing apoptosis. Furthermore, we show that IRF-1-induced apoptosis appears to be independent of any soluble factor, suggesting that IRF-1-induced apoptosis is ligand-independent. Our model supports the existence of a FADD/caspase-8 dependent but ligand-independent apoptotic pathway and supports the concept of a death inducing complex formation intracellularly rather than exclusively at the cell surface.
Results

IFN-g induces IRF-1-mediated apoptosis of breast cancer cells
When we previously observed IFN-g induced growth suppression correlating to IRF-1 induction, we hypothesized that this was the result of apoptosis (Yim et al., 2003) . Through time course experiments in MDA468, we have found that IFN-g induces apoptosis ( Figure 1a ) as early as 20 h with both Annexin V positive, PI negative cells (early apoptosis) and Annexin V-positive, PI-positive cells (late apoptosis), continuing to increase for the duration of the time course. Figure 1b shows the total apoptotic (total Annexin V positive) fraction in cells treated in triplicate compared to untreated cells, for which an increasingly significant difference in apoptosis is seen from 20 h on.
Since we correlated IRF-1 expression with IFN-ginduced growth suppression and now apoptosis, we confirmed the role of IRF-1 in IFN-g-induced apoptosis of MDA468 using siRNA (small interfering RNA) technology. siRNA against IRF-1, but not scrambled control siRNA resulted in reduction of IRF-1 expression by immunoblotting (Figure 1c, upper panel) , and resulted in statistically significant inhibition of IFN-g-induced apoptosis (Figure 1c, lower panel) . This is consistent with our previous studies, in which antisense S-oligonucleotides against IRF-1 blocked the growth inhibitory effect of IFN-g in breast cancer cell lines (Yim et al., 2003) .
IRF-1 and IFN-g induces apoptotic cell death, which is entirely caspase-mediated We described previously that breast cancer cell apoptosis by adenoviral transgene expression of IRF-1 Pizzoferrato et al., 2004) . Following infection with either Ad-IRF-1 or Ad-Null (Ad-C5, empty vector control), we examined the time course of the early and late apoptotic response at time points from 24 to 36 h post-infection (Figure 2a) . A significant apoptotic response above that of baseline was detected by 24 h (Figure 2b) , and increased at 36 h (Figure 2a and b). To explore the possible molecular mechanisms involved in this response and confirm that cells treated with Ad-IRF-1 were dying through an apoptotic process, we examined cell death inhibition by the pan-caspase inhibitor ZVAD. Cell death appeared to be due entirely to a caspase-mediated apoptosis since ZVAD completely blocked IRF-1-induced apoptotic cell death at 36 h (Figure 2c ). Furthermore, IFN-g induced cell death also appeared to be blocked by ZVAD, consistent with an IRF-1 and caspase-mediated apoptosis (Figure 2d ).
Screening for individual caspases involved in IRF-1-induced apoptosis
We had demonstrated previously that overexpression of IRF-1 can result in cleaved caspase-3 with subsequent PARP cleavage by immunoblotting, activated caspase-3 by fluorometric assay, and increased caspase-8 mRNA by northern blotting . Here, we confirmed caspase-8 cleavage into the 43/41 kDa and activated 18 kDa fragments (Figures 3 and 4) via immunoblotting. In screening for inhibition of Ad-IRF-1-induced apoptosis compared to baseline (Ad-Null) by specific caspase inhibitors, we found that caspase-3 and -7 inhibiting peptide, DEVD, brought the total apoptosis nearly back to levels seen with Ad-Null (93%, Figure 3 ), as did caspase-8 specific inhibitor, IETD (97%, Figure 3) . The caspase-9-specific inhibitor, LEHD, had much less of an inhibitory effect (30%, Figure 3 ). We confirmed in MDA468 that IRF-1 overexpression results in caspase-3 cleavage into the p19, 17 and 15 products (Figure 3) . Interestingly, ZVAD, DEVD and IETD all nearly completely inhibited apoptosis by Ad-IRF-1, but did not block caspase-8 cleavage to p43/41 and only attenuated the p18 product. Furthermore, these caspase inhibitors did not block caspase-3 cleavage to p19, but did completely block cleavage to p15. In the offset of Figure 3 , it is clear that IRF-1 without inhibitors leads preferentially to the p15 species, while DEVD and IETD may actually increase the p19 product by preventing cleavage to p17 and p15, as does ZVAD ( Figure 3 ). As seen in the offset the activated p20 product of caspase-7 is also attenuated by DEVD and IETD. The slight shift in migration seen for caspase-3, -7 and -8 cleavage products treated with caspase inhibitors may be slower migration owing to the known irreversible binding of the caspase inhibiting peptide to the cleaved product.
We also examined caspase-8, -3 and -7 cleavage as a reflection of caspase activation along a time course. Ad-IRF-1 results in IRF-1 induction (Figure 4 ) by 12 h with induction of caspase-8 cleavage by 24 h, resulting in the 43/41 kDa fragments and the active p18 fragment at 24 h, which is increased at 30 h. Caspase-3 cleavage products ( Figure 4 ) are seen at 24 h and increased at 30 h, with decreased procaspase-3 at 30 h. The active caspase-7 product p20 and depletion of procaspase-7 was seen at 30 h. Since caspase-8 appears to be cleaved and activated and caspase-8 inhibitor IETD appears to block apoptosis, we also assessed for cleavage of bid, which when proteolytically cleaved by caspase-8, acts to release cytochrome c and Smac/DIABLO from the mitochondria. Cleaved bid is seen in the cytosol with loss of the intact form (Figure 4b ) with IRF-1 treatment, and cytochrome c and Smac/DIABLO were released into the cytosol (Figure 4c ).
The role of caspase-8 as the likely apical caspase in IRF-1-induced cell death We therefore focused on the role of caspase-8 as the apical caspase in IRF-1 mediated apoptosis from several aspects. First, we assessed cleavage products and apoptosis in the caspase-8-deficient cell line U373MG. U373MG has extremely low levels of normal, wild type caspase-8, which makes it resistant to death-ligands (Knight et al., 2001) . Despite high levels of IRF-1 expression by immunoblotting, there is no effect on the levels of procaspase-8 and no caspase-8, -3, or -7 cleavage products ( Figure 5a ). U373MG cells transfected with Ad-IRF-1 also lack apoptosis at multiplicity of infection (MOI) of 25, despite >95% transduction ( Figure 5b ). Caspase-8 cannot be reconstituted to U373MG, because caspase-8 expression alone in U373MG results in drastic apoptosis (Shinoura et al., 2000) . We used siRNA against caspase-8 to decrease caspase-8 in MDA468 and found that while we could not completely suppress caspase-8 expression, siRNA against caspase-8 result in statistically significant attenuation of apoptosis against Ad-IRF-1 versus FADD and caspase-8 demonstrate a perinuclear aggregation, which on overlay analysis seems to confirm colocalization of FADD and caspase-8 in a perinuclear location (yellow), which is strikingly similar to that seen as proposed 'death effector filaments' described previously (Perez and White, 1998) , and an intracellular location for FADD/caspase-8 death complexes (Micheau and Tschopp, 2003) . We also performed coimmunoprecipitation studies that confirms binding of FADD to caspase-8 in Ad-IRF-1-treated cells (Supplementary Figure S2) .
Death ligands or a secreted soluble factor is not implicated in IRF-1-induced apoptosis FADD is known to be involved in mediating extrinsic apoptosis by the classical death-ligands tumor necrosis factor (TNF) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and other TNF superfamily members. Treatment with TRAIL alone in MDA468 cells will induce apoptosis (Figure 8a) , however, this cell line is resistant to both TNF-a and FasL-induced apoptosis (data not shown), consistent with studies that show MDA468 cells deficient in Fas (Keane et al., 1996) and unresponsive to FasL or Fas receptor agonists (Billecke et al., 2002) . Nevertheless, after confirming the ability of neutralizing antibody to DR4 and DR5 to block completely the apoptotic effect of TRAIL (Figure 8a ), and confirming that IRF-1 does not induce TRAIL (data not shown), we then used the highest recommended doses of neutralizing antibody for each death ligand/receptor to confirm that secretion of TNF, TRAIL and FasL are not involved in IRF-1-induced apoptosis in MDA468 cells (Figure 8b ). Furthermore, no secreted soluble factor appears to be 
Discussion
While IFN-g and IRF-1 have been described to sensitize cells to apoptosis and specifically sensitize to deathligand-induced apoptosis (Park et al., 2004) , our study examines the direct induction of apoptosis by IFN-g and IRF-1. In these studies, we confirmed IFN-g induction of caspase-mediated apoptosis in MDA468 breast cancer cells and that IRF-1 siRNA inhibited apoptotic induction by IFN-g consistent with other studies (Kim et al., 2002) . We established that adenoviral transgene expression of IRF-1 induces a similar caspase-mediated apoptosis, and since IRF-1 is known to mediate both physiologic and pharmacologic apoptosis we utilized Ad-IRF-1 to facilitate our studies. IRF-1 expression correlated with an apoptotic time course of 24-36 h and this is supported by a matching time-course immunoblot of caspase-8, -3 and -7 cleavages, as well as current literature that associates IRF-1 and caspase cleavage with apoptosis (Pizzoferrato et al., 2004; Kim et al., 2004) . We provide evidence of mitochondrial involvement through immunoblotting of bid, Smac/DIABLO and cytochrome c. Use of specific and pan-caspase inhibitors point to the role of caspase-8 as the apical caspase in the IRF-1 apoptotic pathway. Utilizing caspase-8 deficient cancer cells, and the inhibitors c-FLIP and IETD, we were able to attenuate IRF-1-induced apoptosis and conclude that caspase-8 is a necessary mediator of IRF-1's apoptotic mechanism.
Since we demonstrated c-FLIP inhibition of IRF-1-induced apoptosis, we further investigated FADD activation as a proximal event. Immunofluorescent data displays a degree of FADD/caspase-8 colocalization with perinuclear coalescence that implies the formation of 'death effector filaments' (Perez and White, 1998) . Coimmunoprecipitation studies confirm binding of FADD to caspase-8 (Supplementary Figure S2) . Since previous literature (Kirchhoff et al., 2002; Park et al., 2004) and our own studies have suggested involvement of the extrinsic death pathway in IRF-1-induced IRF-1 induces ligand-independent FADD-mediated apoptosis MT Stang et al apoptosis, we expected the involvement of death receptors and ligands. We found, however, that the involvement of FADD and caspase-8 signaling appeared to be independent of classical death-ligands since neutralizing antibodies were ineffective in abrogating IRF-1 induced apoptosis. Indeed, transwell studies suggest that no soluble or secreted factor mediates IRF-1's apoptotic potential.
As seen in Figure 1 , the apoptosis observed in IFN-g treated breast cancer cells appears to be slower than is seen with classical death ligands. We feel that this may be because of a transcriptional based cascade, for which IRF-1 is a central component. MDA468 cells are uniquely susceptible to IFN-g growth inhibition in our previous studies (Yim et al., 2003) , and we have demonstrated that this is probably owing to apoptotic vulnerability. We hypothesized that pro-oncogenic IRF-2, a transcriptionally competitive inhibitor of IRF-1, induced by IFN-g, contributes to IRF-1 resistance seen in other cancer cell lines (Yim et al., 2003) and would certainly apply to IRF-1-induced apoptosis. We demonstrated previously that the breast cancer cell line SKBR3, which is resistant to IFN-g-induced growth inhibition (Yim et al., 2003) , is susceptible to ectopic 
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MT Stang et al IRF-1 overexpression (Pizzoferrato et al., 2004) , and this may be due to the unopposed effects of IRF-1. With the identification of other IRF's, the interaction between IRF's at the transcriptional level may be much more complex. Nevertheless, IRF-1 appears to be a necessary component of IFN-g-induced apoptosis of MDA468 breast cancer cells. Interestingly, of the few systems in which a ligandindependent FADD/caspase-8-mediated apoptosis occurs, one is with chemotherapy (Tang et al., 1999) . In models of apoptosis in solid cancer cell lines by chemotherapy, there seems to be a longer time course of apoptosis, and a less marked response than those seen by death-ligands, similar to our model. In one study, doxorubicin has been found to upregulate IRF-1 in ERÀ and ER þ breast cancer cell lines (Bouker et al., 2004) , and therefore it is possible that IRF-1 can mediate the ligand-independent FADD/caspase-8-mediated apoptosis seen with certain chemotherapeutics.
Since IRF-1 is a nuclear transcription factor, one would presume that IRF-1 induced FADD/caspase-8-dependent apoptosis would involve transcriptional upregulation of genes that may cause FADD to colocalize with caspase-8. An increase in procaspase-8 may result in auto-proteolytic cleavage even in the absence of FADD (Muzio et al., 1998) . Ruiz-Ruiz et al. (2004) has very convincingly shown that caspase-8 is upregulated by IFN-g through IRF-1 in MCF-7 breast cancer cells. We also demonstrated increased caspase-8 expression by northern blot in forced expression of IRF-1 in another breast cancer cell line . While this can clearly be a factor in FADD/caspase-8-mediated apoptosis by IRF-1, we did not find increased caspase-8 mRNA by quantitative real-time RT-PCR in our cells despite confirming increased caspase-8 mRNA in MCF-7 (Supplementary Figure S3) . Our data support additional mechanisms for caspase-8 activation beyond simple transcriptional upregulation of caspase-8.
We also assessed for differences in FADD expression in response to IRF-1 treatment by immunoblotting and found no induction of FADD protein (Figure 6a) . Additionally, we have not found an increase in FADD expression on microarray analysis (data not shown). Previously, we demonstrated an increase in caspase-7 expression and Bak expression in a different breast cancer cell line , which could certainly participate in induction of apoptosis, but based on the known understanding of these proteins it is unlikely that these proteins would contribute to the FADD/caspase-8 interaction. The mechanism of the IRF-1-induced FADD/caspase-8 interaction needs further study. 
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We previously demonstrated the role of caspases in IRF-1 mediated apoptosis, but did not completely block apoptosis with pan-caspase inhibitor, which could imply a non-caspase mediated or necrotic pathway (Pizzoferrato et al., 2004; Kim et al., 2004) . However, in our current study, we were able to completely abrogate apoptosis using the pan-caspase inhibitor ZVAD, which appears to confirm that in our current model not only is the cell death observed occurring through apoptosis, but also that it is completely caspase mediated. The specific caspase inhibitor IETD also appears to nearly completely block apoptosis as well, but our data does imply less specificity for caspase-8, since it appears that there is a slight shift in mobility in activated caspase-3 on immunoblot, which could be attributed to the irreversible binding of the caspase inhibiting peptide to caspase-3 in addition to caspase-8 (Figure 4) . However, we feel that by demonstrating inhibition of apoptosis by the use of caspase-8-deficient cells, by upregulating c-FLIP, and by demonstrating colocalization of caspase-8 with FADD this confirms the essential role of caspase-8 and the caspase-8/FADD interaction in IRF-1-induced apoptosis in our breast cancer cell line.
Finally, we have demonstrated a rare example of a ligand-independent FADD/caspase-8-mediated apoptosis in our model. There have been few other studies demonstrating a non-death-ligand, but FADD/caspase-8-dependent apoptosis (for a review of studies see Supplementary information). None of the studies addressed the role of soluble factors using transwells, because with almost all the studies, the inducing agent for apoptosis was also a soluble factor. IRF-1 is an intracellular protein that is not released by cells.
In conclusion, our studies further confirm a central role of the FADD/caspase-8 death pathway in apoptosis that does not necessarily require death ligands. Since IRF-1 is a transcription factor, it is certainly possible that IRF-1 upregulates an intracellular protein or proteins that recruit(s) FADD to caspase-8 and it is also possible that IRF-1 is itself involved in such a recruitment. These hypotheses require further study.
Materials and methods
Chemicals and reagents
Antibodies (Abs): rabbit polyclonal Abs to caspase-3, caspase-7 and bid; and monoclonal Abs (mAbs, clone if listed) to caspase-8 (1C12) and Smac/DIABLO (Cell Signaling Technology, Danvers, MA, USA); rabbit polyclonal Abs to IRF-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and FADD (Stressgen, Ann Arbor, MI, USA); mAbs to Fas (ZB4, Upstate Biotechnology, Lake Placid, NY, USA), TNFR-1 (H398, Biosource International, Carlsbad, CA, USA), DR4 (HS101, Axxora, San Diego, CA, USA), DR5 (HS201, Axxora), cytochrome c (BioVision, Mountainview, CA, USA). IFN-g was purchased from PBL Biomedical (Piscataway, NJ, USA). Crosslinked 'killer' TRAIL was purchased from Axxora. The construction and characterization of E1, E3-deleted non-replicating recombinant adenoviruses Ad-C5 (empty vector control, Ad-Null), Ad-IRF-1 and Ad-EGFP (enhanced green fluorescent protein) were described previously , as were recombinant adenovirus expressing c-FLIP and LacZ (Wang et al., 2005) , and were provided by Dr Andrea Gambotto from the Vector Core at the University of Pittsburgh (www.vectorcore.pitt.edu). Dimethylsulfoxide (DMSO) was obtained from ATCC (Manassas, VA, USA), and ZVAD (irreversible pan-caspase inhibitor) from Promega (Madison, WI, USA). The irreversible caspase inhibitors DEVD, IETD and LEHD were obtained from CalBiochem (La Jolla, CA, USA). siRNA specific to IRF-1, scrambled IRF-1 control, and siPORT Amine transfection reagent were purchased from Ambion (Austin, TX, USA).
Cell lines and culture p53 mutated MDA468 (MDA-MB-468) was purchased from ATCC. The p53 mutated, caspase-8-deficient cell line, U373MG was provided by Dr Dai-Wu Seol MDA468 tumor cells were propagated in 1:1 Dulbecco's modified Eagle's medium (DMEM) (BioWhittaker Inc., Walkersville, MD, USA) and Ham's F-12 (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS), L-glutamine and antibiotics. U373MG were propagated in DMEM with 10% FBS, 2 mM L-glutamine and antibiotics. All cell cultures were maintained in 5% CO 2 at 371C.
Apoptosis assay
Annexin V-FITC apoptosis analysis was performed as described previously (Pizzoferrato et al., 2004) with percent apoptosis indicated in bar graphs representing the mean percent of gated cells that were found in the early and late apoptotic groupings in the appropriate quadrants. Error bars are s.d.
Immunoblotting analysis
Western blotting was performed as described previously .
Inhibition of IRF-1-induced caspase cleavage MDA468 cells were treated with no treatment, IFN-g (1000 units/ml), Ad-Null or Ad-IRF-1 (MOI 25) with either DMSO, ZVAD, DEVD, IETD, or LEHD at 100 mM. Alternatively no treatment, Ad-Null or Ad-IRF-1 (MOI 25) were transfected into cells treated with Ad-c-FLIP or Ad-LacZ. Cells were harvested at indicated time points after treatment and either analysed for apoptosis by flow cytometry or immunoblotted.
Knockdown of IRF-1 and FADD Pre-designed siRNA specific to IRF-1 20 nM , scrambled IRF-1 control, or nothing was transfected into cells using siPortAmine transfection reagent in accordance with manufacturer's instructions (Ambion), and incubated overnight before treatment. Transfection was optimized using varying amounts of fluorescently labeled siRNA (siFAM) and transfection reagent in the MDA468 cells.
The FADD DN selectable expression vector and its empty vector control, NEO, were a generous gift from Dr V Dixit (Genentech, San Francisco, CA, USA). Stable bulk transfectants were generated by transfecting the respective plasmid using FuGene (Roche, Basel, Switzerland) per the manufacturers protocol followed by selection with 600 mg/mL of G418. Bulk transfectants were then used for study, with confirmation of FADD DN expression by immunoblotting.
Cellular fractionation MDA468 cells were treated with either no treatment, IFN-g (1000 units/ml), Ad-Null or Ad-IRF-1 (MOI 25). Cellular IRF-1 induces ligand-independent FADD-mediated apoptosis MT Stang et al fractionation followed mitochondrial/cytosol fractionation kit (BioVision) instructions with the exception that the mitochondrial pellet was resuspended in 50 ml of mitochondrial buffer.
Immunofluorescence MDA468 cells cultured on cover slips were treated with AdNull or Ad-IRF-1 (MOI 25) for 24 h. Cells were fixed in 2% paraformaldehyde and permeabilized with 0.1% Triton-X in PBS for 15 min. After washing in PBS and 0.5% BSA, cells were blocked with 1% BSA and 5% goat serum (Sigma) for 45 min. Cells were probed with FADD antibody (1:500 dilution) followed by incubation with a FITC labeled secondary anti-rabbit IgG antibody (Jackson ImmunoResearch, West Grove, PA, USA). Cells were subsequently probed with caspase-8 antibody (1:500 dilution) and a Cy5 labeled secondary anti-mouse IgG antibody (Jackson ImmunoResearch). Nuclei were stained with DRAQ5 (Biostatus Ltd, Leicestershire, UK). Several representative images ( Â 40 magnification) of the cells were taken with an Olympus BX51 fluorescent microscope (Olympus America, Melville, NY, USA).
Assessment of death ligands by neutralizing antibodies
MDA468 cells were treated with antibody to Fas (1 mg/ml), TNFR-1 (10 mg/ml), DR4 (10 mg/ml) and/or DR5 (10 mg/ml) after adhering overnight. Cells were treated with no treatment, Ad-Null or Ad-IRF-1 (MOI 25) or crosslinked 'killer' TRAIL at 100 ng/ml. Cells were harvested after 24 or 48 h and assayed for apoptosis.
Transwell coculture assessment of apoptosis MDA468 cells were cultured in a six-well plate and Transwell coculture insert (Corning Inc., Corning, NY, USA). Cells were treated with no treatment (NT), TRAIL (100 ng/ml), or transfected with Ad-Null or Ad-IRF-1 (MOI 25). After 4 h incubation, the wells were washed three times and media was replenished, except in the TRAIL treated parental wells, which retained their media. Each well then received a Transwell insert containing cultured cells. Transwell inserts have 0.4 mM pores that allow flow through secreted and soluble factors. After 24 h cells from both the parental plate and the corresponding transwell were harvested and analysed for apoptosis.
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